Vijay Nema

Dr. Vijay Nema

ICMR-National Institute of Research in Tribal Health, Jabalpur, India
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
RWRushabh Waghmode
Rushabh Waghmode
SJSushama Jadhav
Sushama Jadhav
VNVijay Nema
Vijay Nema
As per the 2019 report of the National Health Portal of India, 41,996,260 cases and 3,740 deaths from respiratory infections were recorded across India in 2018. India contributes to 18% of the global population, with severe acute respiratory infection (SARI) as one of the prominent causes of mortality in children >5 years of age. Measures in terms of the diagnosis and surveillance of respiratory infections are taken up globally to discover their circulating types, detect outbreaks, and estimate the disease burden. Similarly, the purpose of this review was to determine the prevalence of respiratory infections in various regions of India through published reports. Understanding the pattern and prevalence of various viral entities responsible for infections and outbreaks can help in designing better strategies to combat the problem. The associated pathogens comprise respiratory syncytial virus (RSV), rhinovirus, influenza virus, parainfluenza virus, adenovirus, etc. Identification of these respiratory viruses was not given high priority until now, but the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has sensitized our system to be alert about the burden of existing infections and to have proper checks for emerging ones. Most of the studies reported to date have worked on the influenza virus as a priority. However, the data describing the prevalence of other respiratory viruses with their seasonal pattern have significant epidemiological value. A comprehensive literature search was done to gather data from all geographical regions of India comprising all states of India from 1970 to 2020. The same has been compared with the global scenario and is being presented here.

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
SUSHAMA DHANANJAY JADHAVSUSHAMA DHANANJAY JADHAV
SUSHAMA DHANANJAY JADHAV
VNVijay Nema
Vijay Nema
HIV‐1 can incite activation of chemokine receptors, inflammatory mediators, and glutamate receptor‐mediated excitotoxicity. The mechanisms associated with such immune activation can disrupt neuronal and glial functions. HIV‐associated neurocognitive disorder (HAND) is being observed since the beginning of the AIDS epidemic due to a change in the functional integrity of cells from the central nervous system (CNS). Even with the presence of antiretroviral therapy, there is a decline in the functioning of the brain especially movement skills, noticeable swings in mood, and routine performance activities. Under the umbrella of HAND, various symptomatic and asymptomatic conditions are categorized and are on a rise despite the use of newer antiretroviral agents. Due to the use of long‐lasting antiretroviral agents, this deadly disease is becoming a manageable chronic condition with the occurrence of asymptomatic neurocognitive impairment (ANI), symptomatic mild neurocognitive disorder, or HIV‐associated dementia. In‐depth research in the pathogenesis of HIV has focused on various mechanisms involved in neuronal dysfunction and associated toxicities ultimately showcasing the involvement of various pathways. Increasing evidence‐based studies have emphasized a need to focus and explore the specific pathways in inflammation‐associated neurodegenerative disorders. In the current review, we have highlighted the association of various HIV proteins and neuronal cells with their involvement in various pathways responsible for the development of neurotoxicity.

1 June 2007 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
VNVijay Nema
Vijay Nema
RARanu Agrawal
Ranu Agrawal
DKDev Vrat Kamboj
Dev Vrat Kamboj
AGAjay Kumar Goel
Ajay Kumar Goel
LSLokendra Singh
Lokendra Singh

1 August 2017 in Biochimie
Verified
Journal Article
Closed access
JBJoyita Banerjee
Joyita Banerjee
VNVijay Nema
Vijay Nema
YDYogita Dhas
Yogita Dhas
NMNeetu Mishra
Neetu Mishra

1 January 2012 in Lung India
Verified
Journal Article
Open access
PDF file
VNVijay Nema
Vijay Nema
Tuberculosis (TB) has been a disease affecting almost all parts of the world since ages. Lot many efforts came in the past for improving diagnosis and treatment. Also, an effective vaccine has been sought after for long. With the emergence of resistant strains of Mycobacterium tuberculosis, the causal organisms of tuberculosis, and complexities emerging due to other associated infections and disease conditions, there is a desperate need for further research input in the field. Be it the better medication and care or better resistance management, proper diagnostics holds the key to success. It has been observed that a high burden of the disease was accompanied by resource limitations and poor research set-up. The scenario remained like this for several decades. With the refreshed vision of resourceful countries and funding agencies, funding is being provided in many areas of research in tuberculosis diagnosis and treatment. This review has been written with an aim to bring forth the limitations of available methods in the field of diagnostics and making researchers aware about the changing scenario with better funding opportunities and support. The author visualizes an enthusiasm from all over the world for the development of better modalities and urges scientists to join the struggle at this very perfect time to take the challenge and come forward with innovations in this field.

28 September 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
PJPratiksha Jadaun
Pratiksha Jadaun
CSChandrabhan Seniya
Chandrabhan Seniya
SPsudhir kumar pal
sudhir kumar pal
SKSANJIT KUMAR
SANJIT KUMAR
PKPramod Kumar
Pramod Kumar
AMAnupam Mukherjee
Anupam Mukherjee
Antiretroviral therapy is the single existing therapy for patients infected with HIV; however, it has drawbacks in terms of toxicity and resistance. Thus, there is a continuous need to explore safe and efficacious anti-retroviral agents. C-Phycocyanin (C-PC) is a phycobiliprotein, which has been known for various biological properties; however, its effect on HIV-1 replication needs revelation. This study aimed to identify the inhibitory effects of C-PC on HIV-1 using in vitro and in silico approaches and to assess its role in the generation of mitochondrial reactive oxygen species (ROS) during HIV-1 infection. In vitro anti-HIV-1 activity of C-PC was assessed on TZM-bl cells through luciferase gene assay against four different clades of HIV-1 strains in a dose-dependent manner. Results were confirmed in PBMCs, using the HIV-1 p24 antigen assay. Strong associations between C-PC and HIV-1 proteins were observed through in silico molecular simulation-based interactions, and the in vitro mechanistic study confirmed its target by inhibition of reverse transcriptase and protease enzymes. Additionally, the generation of mitochondrial ROS was detected by the MitoSOX and DCF-DA probe through confocal microscopy. Furthermore, our results confirmed that C-PC treatment notably subdued the fluorescence in the presence of the virus, thus reduction of ROS and the activation of caspase-3/7 in HIV-1-infected cells. Overall, our study suggests C-PC as a potent and broad in vitro antiviral and antioxidant agent against HIV-1 infection.